Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Share-based Compensation (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Share-based Compensation readings, the most recent being $58.6 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 11.75% to $58.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $217.9 million, a 11.46% increase, with the full-year FY2025 number at $217.9 million, up 11.46% from a year prior.
  • Share-based Compensation hit $58.6 million in Q4 2025 for Neurocrine Biosciences, up from $53.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $68.5 million in Q2 2023 to a low of $28.6 million in Q2 2021.
  • Median Share-based Compensation over the past 5 years was $43.3 million (2022), compared with a mean of $45.8 million.
  • The widest YoY moves for Share-based Compensation: up 74.28% in 2024, down 37.08% in 2024.
  • Neurocrine Biosciences' Share-based Compensation stood at $35.6 million in 2021, then grew by 22.19% to $43.5 million in 2022, then dropped by 12.41% to $38.1 million in 2023, then surged by 74.28% to $66.4 million in 2024, then dropped by 11.75% to $58.6 million in 2025.
  • The last three reported values for Share-based Compensation were $58.6 million (Q4 2025), $53.7 million (Q3 2025), and $52.8 million (Q2 2025) per Business Quant data.